Mark A. Gurney

Hematology
200 1st St Sw
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia.

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia.

Journal: Blood cancer discovery
Published: July 17, 2025

Acute Megakaryoblastic Leukemia Masquerading as a Germ Cell Tumor.

Acute Megakaryoblastic Leukemia Masquerading as a Germ Cell Tumor.

Journal: American journal of hematology
Published: April 13, 2025

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.

Journal: Leukemia
Published: March 19, 2025

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.

Journal: Blood advances
Published: March 18, 2025

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia.

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia.

Journal: Blood
Published: October 21, 2024

PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.

PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.

Journal: American journal of hematology
Published: September 16, 2024

ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia.

ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia.

Journal: Haematologica
Published: March 04, 2024

Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.

Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.

Journal: JAMA oncology
Published: February 22, 2024

The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.

The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.

Journal: Blood advances
Published: December 07, 2023

NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models.

NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models.

Journal: Heliyon
Published: November 30, 2023

Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.

Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.

Journal: Haematologica
Published: August 29, 2023

TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.

TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.

Journal: Leukemia research
Published: July 06, 2023
Showing 1-12 of 35

Last Updated: 09/26/2026